The notable increase in Ginkgo Bioworks' consensus price target reflects significantly improved net profit margins and a marked decline in future P/E, resulting in a fair value revision from $8.67 to $10.33.
What's in the News
- Ginkgo Bioworks reaffirmed its full-year 2025 revenue guidance at $167 million to $187 million.
- The Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory selected Ginkgo Automation to deploy a $4.66 million automated anaerobic phenotyping platform, enhancing research throughput and enabling remote, AI-driven workflows.
- Ginkgo Bioworks launched a new high-throughput, cost-competitive ADME profiling service through Ginkgo Datapoints, targeting rapid, AI-ready datasets for drug discovery and machine learning applications.
- Ginkgo Bioworks was added to numerous Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks, increasing index-related visibility.
- Mark Dmytruk will step down as CFO, with Chief Accounting Officer Steven Coen, CPA, set to assume the CFO role, bringing extensive experience from Charles River Laboratories and other leadership positions.
Valuation Changes
Summary of Valuation Changes for Ginkgo Bioworks Holdings
- The Consensus Analyst Price Target has significantly risen from $8.67 to $10.33.
- The Net Profit Margin for Ginkgo Bioworks Holdings has significantly risen from 8.54% to 14.18%.
- The Future P/E for Ginkgo Bioworks Holdings has significantly fallen from 56.87x to 34.17x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.